NCT06390865
Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With TSC1 or TSC2 Genetic Changes (MATCH - Subprotocol M)
At risk: Primary completion moved at least 6 months later.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 13 versions: 6 with changes below, 7 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Primary and study completion pushed from Dec 31, 2026 to Jun 30, 2027
- Notable Eligibility criteria expanded, about 27 words
- Secondary endpoints: details revised at 3 of 3 entries
- Study description revised
- Notable Primary and study completion dates: Dec 31, 2025 to Dec 31, 2026v8
- Minor Interventions: Biopsy (Procedure), Biospecimen Collection (Procedure), Computed Tomography (Procedure), Magnetic Resonance Imaging (Procedure)… to Biopsy Procedure (Procedure), Biospecimen Collection (Procedure), Computed Tomography (Procedure), Magnetic Resonance Imaging (Procedure)…v5
- Notable Primary and study completion dates: Jan 6, 2025 to Dec 31, 2025v3
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (3)
Arms and interventions
Patients receive sapanisertib (MLN0128 \[TAK-228\]) PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo CT or MRI during screening and on study, as well as during follow-up as clinically necessary. Patients also undergo biopsies and blood sample collection on study.
Procedures: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
Drugs: Sapanisertib
Sites
1 site in 1 country
- ECOG-ACRIN Cancer Research GroupPhiladelphia, Pennsylvania, United States